Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C19H24NO3.Ca.2H2O |
| Molecular Weight | 704.906 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.[Ca++].[H][C@@]12CN(C[C@]1([H])CCCC2)C(=O)C[C@H](CC3=CC=CC=C3)C([O-])=O.[H][C@@]45CN(C[C@]4([H])CCCC5)C(=O)C[C@H](CC6=CC=CC=C6)C([O-])=O
InChI
InChIKey=QEVLNUAVAONTEW-UZYHXJQGSA-L
InChI=1S/2C19H25NO3.Ca.2H2O/c2*21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14;;;/h2*1-3,6-7,15-17H,4-5,8-13H2,(H,22,23);;2*1H2/q;;+2;;/p-2/t2*15-,16+,17-;;;/m00.../s1
| Molecular Formula | HO |
| Molecular Weight | 17.0073 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C19H25NO3 |
| Molecular Weight | 315.4067 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | Ca |
| Molecular Weight | 40.078 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Mitiglinide is a drug for the treatment of type 2 diabetes currently marked under tradename Glufast. Glufast® is available as the tablet for oral use, containing 5 mg or 10 mg of Mitiglinide calcium hydrate. The recommended dose is 10 mg three times daily just before each meal (within 5 minutes). Mitiglinide was approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on January 29, 2004, and is currently co-marketed in Japan by Kissei and Takeda. Mitiglinide is a rapid-acting insulin secretion-stimulating agent, its belongs to the meglitinide (glinide) class of blood glucose-lowering drugs. Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of KAD-1229, a nonsulfonylurea hypoglycemic agent, on plasma glucose and insulin in streptozotocin-induced diabetic dogs. | 2001 Feb |
|
| The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. | 2001 Nov 9 |
|
| Effects of S 21403 on hormone secretion from isolated rat pancreas at different glucose concentrations. | 2002 Dec 5 |
|
| [Significance of insulin secretion pattern lectured by "glinides" in the treatment of postprandial hyperglycemia]. | 2005 Dec |
|
| Characterization of the action of S 21403 (mitiglinide) on insulin secretion and biosynthesis in normal and diabetic beta-cells. | 2005 Nov |
|
| Effects of mitiglinide and sulfonylureas in isolated canine coronary arteries and perfused rat hearts. | 2006 Feb 15 |
|
| [Glinide(s), sulfonylurea(s)]. | 2006 Nov |
|
| Imaging docking and fusion of insulin granules induced by antidiabetes agents: sulfonylurea and glinide drugs preferentially mediate the fusion of newcomer, but not previously docked, insulin granules. | 2006 Oct |
|
| Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study. | 2007 Feb |
|
| Effect of mitiglinide on glycemic control over 52 weeks in Japanese type 2 diabetic patients insufficiently controlled with pioglitazone monotherapy. | 2009 |
|
| Ca(2+) channels on the move. | 2009 Dec 29 |
|
| Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis. | 2010 Feb |
|
| A prospective, randomized, multicenter trial comparing the efficacy and safety of the concurrent use of long-acting insulin with mitiglinide or voglibose in patients with type 2 diabetes. | 2015 |
Patents
Sample Use Guides
The recommended dose is 10 mg three times daily just before each meal (within 5 minutes).
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:26:56 GMT 2023
by
admin
on
Fri Dec 15 16:26:56 GMT 2023
|
| Record UNII |
9651C21W3Z
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DBSALT001868
Created by
admin on Fri Dec 15 16:26:57 GMT 2023 , Edited by admin on Fri Dec 15 16:26:57 GMT 2023
|
PRIMARY | |||
|
m7566
Created by
admin on Fri Dec 15 16:26:57 GMT 2023 , Edited by admin on Fri Dec 15 16:26:57 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID5046728
Created by
admin on Fri Dec 15 16:26:57 GMT 2023 , Edited by admin on Fri Dec 15 16:26:57 GMT 2023
|
PRIMARY | |||
|
207844-01-7
Created by
admin on Fri Dec 15 16:26:57 GMT 2023 , Edited by admin on Fri Dec 15 16:26:57 GMT 2023
|
PRIMARY | |||
|
SUB21788
Created by
admin on Fri Dec 15 16:26:57 GMT 2023 , Edited by admin on Fri Dec 15 16:26:57 GMT 2023
|
PRIMARY | |||
|
100000088882
Created by
admin on Fri Dec 15 16:26:57 GMT 2023 , Edited by admin on Fri Dec 15 16:26:57 GMT 2023
|
PRIMARY | |||
|
9651C21W3Z
Created by
admin on Fri Dec 15 16:26:57 GMT 2023 , Edited by admin on Fri Dec 15 16:26:57 GMT 2023
|
PRIMARY | |||
|
6918235
Created by
admin on Fri Dec 15 16:26:57 GMT 2023 , Edited by admin on Fri Dec 15 16:26:57 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |